Abstract: The invention relates to a sequence of nucleotides, characterized in that it comprises at least a part of a sequence coding for a protein with urease activity such as that expressed by C. pylori.Another subject of the invention is the use of this sequence, in particular for the in vitro diagnosis of diseases associated with the presence of Campylobacter pylori in the organism of an individual.
Type:
Grant
Filed:
June 5, 1990
Date of Patent:
December 9, 1997
Assignees:
Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
Abstract: The invention relates to a polypeptide characterized in that it contains at least one peptide sequence carrying one or several epitopes characteristic of a protein produced at the sporozoite stage and in the hepatocytes infected by P. falciparum, this sequence comprising a sequence of from 10 amino acids to the maximal number of amino acids of the following peptide chain sequence:Glu-Phe-Arg-Val-Ser-Thr-Ser-Asp-Thr-Pro-Gly-Gly-Asn-Glu-Ser-Ser-Ser-Ala-Ser -Pro-Asn-Leu-Ser-Gly-Ala-Arg-Glu-Lys-Lys-Asp-Glu-Lys-Glu-Ala-Ser-Glu-Gln-Gl y-Glu-Glu-Ser-His-Lys-Lys-Glu-Asn-Ser-Gln-Glu-Ser-Ala-Asn-Gly-Lys-Asp-Asp-V al-Lys-Glu-Glu-Lys-Lys-Thr-Asn-Glu-Lys-Lys-Asp-Asp-Gly-Lys-Thr-Asp-Lys-Val- Gln-Glu-Lys-Val-Leu-Glu-Lys-Ser-Pro-Lys-Glu-Phe.It also relates to the use of these polypeptides, as well as the nucleotide sequences coding for these polypeptides, in methods of in vitro diagnosis of malaria on a biological sample derived from the individual in whom the disease is to be detected.
Type:
Grant
Filed:
May 13, 1994
Date of Patent:
November 25, 1997
Assignee:
Institut Pasteur
Inventors:
Pierre Druilhe, Claudine Guerin-Marchand
Abstract: The subject of the present invention is thus a nucleotide sequence which hybridizes specifically with a Campylobacter jejuni genomic nucleic acid sequence chosen from the nucleotide sequence SEQ ID No. 1, the nucleotide sequence SEQ ID No. 2 the sequences complementary to the latter, as well as the sequences differing therefrom by nutation, insertion, deletion or substitution of one or more bases, and which does not or virtually does not hybridize with nucleic acids from other Campylobacter species.Fragments of this sequence can be used as specific primers for the amplification of sequences specific for Campylobacter jejuni and as nucleic probes specific for Campylobacter jejuni nucleic sequences.The subject of the invention is also a method of detecting the presence of Campylobacter jejuni stains in a biological sample, as well a kit for carrying out the method.
Abstract: Compositions comprise one or more B epitopes of the envelope glycoprotein of a retrovirus and one or more T epitopes of the envelope glycoprotein from a distinct retrovirus, or a T epitope from a different protein of the same retrovirus as the B epitope. In particular, the retrovirus is a human immunodeficiency virus (HIV) or a simian immunodeficiency virus (SIV), human T-cell lymphotropic virus type 1 (HTLVI), or human T-cell lymphotropic virus type II (HTLVII).
Type:
Grant
Filed:
November 9, 1993
Date of Patent:
November 18, 1997
Assignees:
Institut Pasteur, Universite Pierre et Marie Curie Paris VI
Inventors:
Marc Girard, Jean-Claude Gluckman, El Mustapha Bahraoui
Abstract: The invention relates to nucleotidic sequences derived from genomes of the HIV-1 type virus, or from genomes of the HIV-2 type virus, or of the SIV type virus, and their applications, especially as oligo-nucleotidic initiators of implementation of an $i (in vitro) method for the diagnosis of the infection of an individual by a virus of the HIV-1 and/or HIV-2 type.
Type:
Grant
Filed:
December 2, 1993
Date of Patent:
November 18, 1997
Assignees:
Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
Abstract: Novel mycoplasmas are described which are prominent in patients who are thought to be suffering from AIDS. Devices are also provided for the in vitro detection of mycoplasmas in biological fluid by means of a reagent which is specific for the mycoplasma group without being specific for particular species within said group. Devices for testing mycoplasma sensitivity to antibiotics are also described.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
November 18, 1997
Assignee:
Institut Pasteur
Inventors:
Luc Montagnier, Alain Blanchard, Anne Marie Di Rienzo, Denise Guetard, Veronique Rame
Abstract: Nucleic sequences from the genome of Salmonella Typhi include all or part of the genetic information required for the in vitro infection of cultured HeLa cells by Salmonella bacteria. Polypeptides encoded by these nucleic sequences are also described, as is the use of said polypeptides and nucleic sequences for implementing methods of in vitro Salmonella detection in biological samples which are thought to contain it.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
October 28, 1997
Assignees:
Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
Abstract: A recombinant plasmid comprises the cyaC and the cyaA genes of Bordetella which directs the expression of Bordetella, adenylate cyclase in a transformed host cell. A recombinant DNA molecule can comprise the Bordetella cyaA gene containing at least one insertion of a heterologous DNA sequence at at least one permissive site. In addition, a recombinant Bordetella adenylate cyclase comprises a heterologous epitope at a permissive site. Methods of inducing a specific B cell, helper T cell, and CTL cell immune response are provided.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
October 21, 1997
Assignee:
Institut Pasteur
Inventors:
Daniel Ladant, Claude Leclerc, Peter Sebo, Agnes Ullmann
Abstract: The present invention relates especially to a highly specific surface for biological reactions, characterized in that it contains a support having at the surface at least one essentially compact layer of an organic compound having, outside the layer, an exposed group containing an ethylenic double bond having affinity for one type of molecule with biological activity under certain reaction conditions, the other elements of the layer being essentially inaccessible for the said molecules under the said reaction conditions.
Type:
Grant
Filed:
February 10, 1995
Date of Patent:
October 14, 1997
Assignee:
Institut Pasteur
Inventors:
David Bensimon, Aaron Bensimon, Fran.cedilla.ois Heslot
Abstract: Novel mycoplasmas are described which are prominent in patients who are thought to be suffering from AIDS. Devices are also provided for the in vitro detection of mycoplasmas in a biological fluid by means of a reagent which is specific for the mycoplasma group without being specific for particular species within said group. Devices for testing mycoplasma sensitivity to antibiotics are also described.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
October 14, 1997
Assignee:
Institut Pasteur
Inventors:
Luc Montagnier, Alain Blanchard, Anne Marie Di Rienzo, Denise Guetard, Veronique Rame
Abstract: A viral vector comprising at least a portion of the genome of the HIV virus, a gene encoding gp160 glycoprotein of the envelope of the HIV virus, as well as the elements providing for the expression of the glycoprotein in cells, wherein the gp160 is expressed as a non-cleavable protein.
Type:
Grant
Filed:
May 17, 1995
Date of Patent:
September 30, 1997
Assignee:
Transgene S.A. and Institute Pasteur
Inventors:
Marie-Paule Kieny, Guy Rautmann, Jean-Pierre Lecocq, Simon Wain Hobson, Marc Girard, Luc Montagnier
Abstract: Polypeptides encoded by genes of papillomavirus HPV39 are provided. Also provided are antibodies directed to the polypeptides, and methods for diagnosing genital neoplasias and for detecting infection by HPV39.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
September 9, 1997
Assignees:
Institut National de la Sante et de la Recherche Medicale, Institut Pasteur
Inventors:
Gerard Orth, Christoph Volpers, Rolf E. Streeck
Abstract: The invention relates to papillomaviruses, particularly to DNA-HPVs isolated from the papillomaviruses IP5 and IP6, the restriction maps of which are presented in FIGS. 10 and 11, and also to probes containing these DNA-HPVs or fragments obtained from them. The invention relates, in addition, to "kits" containing distinct groups of probes, containing one of these DNA-HPVs or DNA-HPV fragments, as well as a procedure for the detection and identification of papillomaviruses which makes use of these different probes.
Type:
Grant
Filed:
April 3, 1995
Date of Patent:
September 9, 1997
Assignees:
Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
Inventors:
Sylvie Beaudenon, Dina Kremsdorf, Odile Croissant, Gerard Orth
Abstract: A composition containing powdered Lactobacillus brevis subsp. coagulans is used to enhance the immunological functions of a patient, particularly with respect to increasing interferon production, 2-5A synthetase activity and Natural Killer activity.
Abstract: Specific DNA sequences derived from the genome of papillomavirus HPV 39 are provided. Also provided are hybridization probes, and methods for diagnosing genital neoplasias and for detecting infection by HPV 39.
Type:
Grant
Filed:
November 16, 1993
Date of Patent:
August 12, 1997
Assignees:
Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
Inventors:
Gerard Orth, Christoph Volpers, Rolf E. Streeck
Abstract: The invention relates to nucleic acid fragments characterized in that they comprise from 8 to 40 nucleotides and in that their sequence is contained either in the DNA coding sequence of the gene for human villin or in any DNA fragment exactly complementary to one of the former and hence containing the same number of deoxynucleotides, or any corresponding RNA fragment containing the same number of ribonucleotides. The invention also relates to the application of these fragments to a procedure for the in vitro detection of the presence of a nucleic acid characteristic of human villin.
Type:
Grant
Filed:
December 9, 1994
Date of Patent:
July 29, 1997
Assignee:
Institut Pasteur
Inventors:
Monique Arpin, Eric Pringault, Alphonse Garcia, Daniel Louvard
Abstract: A nucleic acid sequence which specifically hybridizes with a genomic nucleic acid sequence of strains of the complex Mycobacterium avium-intracellulare selected from nucleotide sequence SEQ ID No 1, nucleotide sequence SEQ ID No 2, complementary sequences thereof, and sequences differing therefrom by the mutation, insertion, deletion or substitution of one or more bases, but does not hybridize with the nucleic acids of mycobacteria which do not belong to said complex. Fragments of the sequence may be used as primers for amplifying sequences which are specific for strains of the complex Mycobacterium avium-intracellulare, and as nucleic probes which are specific for nucleic sequences of strains of the complex Mycobacterium avium-intracellulare. A method for detecting strains of the complex Mycobacterium avium-intracellulare in a biological sample, and a kit for implementing the method, are also provided.
Type:
Grant
Filed:
May 2, 1994
Date of Patent:
July 22, 1997
Assignee:
Institut Pasteur
Inventors:
Jean-Luc Guesdon, Dominique Thierry, Veronique Vincent
Abstract: The invention concerns DNA fragments derived from the genomic DNA of HPV-33. These fragments are selected from the group of fragments extending between the nucleotide extremities defined hereafter in relation to the nucleotide-numbering in FIGS. 1a and 1b respectively:76-556543-864867-28112728-38083326-35753842-40794198-56115516-8091.The invention also relates to the use of these fragments as probes for the detection of HPV in tissue cultures.
Abstract: The invention relates to a nucleotide sequence coding for a cycloheximide resistance protein sensitive to concatenation of amino acids A, or coding for all or part of said optionally modified concatenation A, in as much as the formed protein confers cycloheximide resistance to a recombinant eucaryotic host transformed by the nucleotide sequence coding for said protein, in conditions appropriate for its production. The invention also relates to a sequence containing the DNA coding for the concatenation A and capable of conferring a high level of resistance to cycloheximide in a given host.
Abstract: Antibodies, both polyclonal and monoclonal, recognize and bind human villin. Hybridomas, producing monoclonal antibodies which bind human villin, are also provided.
Type:
Grant
Filed:
April 13, 1995
Date of Patent:
June 3, 1997
Assignees:
Institut Pasteur, Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medical
Inventors:
Daniel Louvard, Brigitte Dudouet, Sylvie Robine, Monique Arpin, Eric Pringault, Alphonse Garcia